Recent Company News

• 08:33 AM ET Nov 11, 2025
  

  Quoin Pharmaceuticals announces achievement of topical rapamycin target loadings for two proprietary delivery technologies ($8.14, 0.00)

• 08:33 AM ET Nov 06, 2025
  

  Quoin Pharmaceuticals reports Q3 EPS ($6.71) vs FactSet ($4.29) [2 est, ($6.65)-(1.92)] ($9.65, 0.00)

• 08:33 AM ET Oct 28, 2025
  

  Quoin Pharmaceuticals provides 9 month 'whole body' data update from ongoing study of QRX003 and announces recruitment of three additional patients in investigator pediatric Netherton syndrome study ($13.20, 0.00)

• 08:32 AM ET Oct 21, 2025
  

  Quoin Pharmaceuticals announces U.S. FDA grants Orphan Drug Designation for QRX003 in Netherton Syndrome ($16.36, 0.00)

• 09:28 AM ET Oct 10, 2025
  

  Quoin Pharmaceuticals announces private placement financing of up to $104.5M ($8.16, 0.00)

• 08:34 AM ET Aug 18, 2025
  

  Quoin Pharmaceuticals appoints Sally Lawlor as new CFO, effective immediately ($7.48, 0.00)

• 08:32 AM ET Aug 07, 2025
  

  Quoin Pharmaceuticals reports Q2 EPS ($6.28) vs FactSet ($6.82) [2 est, ($6.83)-(6.81)] ($7.37, 0.00)

• 08:34 AM ET Jul 29, 2025
  

  Quoin Pharmaceuticals provides product portfolio update ($8.16, 0.00)

• 05:09 PM ET Jul 08, 2025
  

  Quoin Pharmaceuticals CFO Gordon Dunn to leave company - 8-K ($8.73, 0.00)

• 07:33 AM ET May 22, 2025
  

  Quoin Pharmaceuticals announces FDA clearance to initiate second pivotal whole body QRX003 Netherton Syndrome clinical study ($8.47, 0.00)